首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1731735

2026 年至 2032 年乳癌藥物市場（按藥物類別、治療方法和地區分類）

Breast Cancer Therapeutics Market By Drug Class (HER2 Inhibitors, Mitotic Inhibitors), Therapy (Chemotherapy, Radiation Therapy), & Region for 2026-2032

出版日期: 2025年04月29日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

乳癌藥物市場評估（2026-2032）

全球乳癌發生率的上升推動了對新治療方法的需求。診斷技術的進步使得早期診斷成為可能，從而導致越來越多的患者尋求治療方案。此外，人們對乳癌的認知不斷提高以及頻繁篩檢的重要性也導致了乳癌確診病例的增加。標靶治療藥物和免疫療法的出現正在改變治療技術，為患者提供更有效、更個人化的選擇。

此外，製藥公司對研發的大量投資將刺激藥物配方的創新，從而推動新治療方法在市場上的推出，預計 2026 年至 2032 年期間的複合年成長率約為 8.30%。

乳癌藥物市場定義/概述

乳癌藥物包括多種乳癌治療方法，包括化療、標靶治療、荷爾蒙療法、免疫治療等。這些治療方法旨在殺死癌細胞、防止復發和提高患者存活率。治療方法適用於乳癌的所有階段，從早期發現和治療到晚期疾病管理，並根據個別患者特徵和腫瘤生物學特性進行調整。目前的研究旨在開發更有效、毒性更小的治療方法、改進個人化醫療技術以及引入基因治療和奈米醫學等新技術，乳癌治療的未來看起來令人樂觀。隨著人們對乳癌意識的提高，將會出現改善患者預後和生活品質的新藥，並有望大幅改變乳癌治療的面貌。

遺傳易感性的日益普及會推動乳癌藥物市場的發展嗎？

乳癌遺傳易感性的不斷增加正成為乳癌治療界的一個主要驅動力。隨著知識的增加和基因檢測的普及，更多的人將能夠識別遺傳風險因素，從而實現早期療育和專門的治療選擇。根據美國國家癌症研究所的數據，約有 510% 的乳癌病例是遺傳性的，是由父母遺傳給孩子的缺陷基因引起的。 2024 年 3 月發表在《臨床腫瘤學雜誌》上的一項具有里程碑意義的研究發現，2019 年至 2023 年間，接受 BRCA1 和 BRCA2 突變基因檢測的女性數量增加了 67%。增加檢測可以實現更早的發現和應對，從而推動對預防措施和標靶治療的需求。

2023年5月，Astra Zeneca報告稱，其用於治療BRCA突變乳癌的PARP抑制劑Lynparza的銷售額與前一年同期比較增28%。同樣，Myriad Genetics 在 2024 年 1 月宣布，其 BRACAnalysis CDx 測試（用於識別 BRCA 基因突變患者）的需求比前一年增加了 35%。在監管方面，美國食品藥物管理局（FDA）於2023年核准了兩種針對BRCA突變乳癌的新型標靶治療，擴大了具有遺傳風險的患者的治療選擇。此外，2023年9月，美國國立衛生研究院宣布了一項5000萬美元的計劃，旨在加強人們獲得基因檢測和諮詢服務的機會，特別是在弱勢群體中。這些進展，加上美國癌症協會預測，到 2024 年，美國女性將確診 297,790 例新的侵襲性乳癌病例，凸顯了在乳癌治療中治療遺傳風險的必要性日益增加。

晚期化療費用的上漲會阻礙乳癌藥物市場的成長嗎？

預計晚期化療費用的上升將限制許多患者獲得這種重要治療方法的機會，從而阻礙乳癌藥物市場的成長。由於醫療保健系統面臨預算限制和處方箋價格上漲，患者可能難以支付自付費用，尤其是在保險覆蓋有限的地區。這些成本障礙可能導致治療開始延遲、處方藥依從性差，最終導致健康狀況不佳，嚴重影響整體市場成長。

此外，成本上升可能導致醫療保健提供者和付款人實施更嚴格的報銷標準，從而使創新的新治療方法更難獲得市場認可。因此，製藥公司可能會發現推出和行銷先進的化療變得更加困難，導致研發投資減少。這可能會阻礙創新治療，阻止可能挽救生命的治療方法進入市場，限制市場擴張並減少患者和醫療保健提供者可用的選擇數量。

The rising global incidence of breast cancer is fuelling need for new therapeutic alternatives. Advances in diagnostic technologies enable earlier diagnosis, resulting in a greater number of patients seeking therapeutic measures. Furthermore, the increased awareness of breast cancer and the significance of frequent tests contribute to the increase in diagnosed cases. The emergence of targeted medicines and immunotherapies has transformed treatment techniques, giving patients more effective and individualized options is surpassing USD 30.52 Billion in 2024 and reaching USD 54.52 Billion by 2032.

Furthermore, pharmaceutical corporations' significant investments in research and development stimulate innovation in medication formulations, leading to the launch of new treatments in the market is expected to grow at a CAGR of about 8.30% from 2026 to 2032.

Breast Cancer Therapeutics Market: Definition/ Overview

Breast cancer medicines include a variety of treatments for breast cancer, such as chemotherapy, targeted therapy, hormone therapy, and immunotherapy. These therapies aim to kill cancer cells, prevent recurrence, and increase patient survival rates. Applications cover all stages of breast cancer, from early detection and treatment to advanced disease management, and are adapted to individual patient features and tumour biology. The future of breast cancer therapies seems optimistic, with current research aimed at producing more effective and less toxic treatment alternatives, improving personalized medicine techniques, and incorporating emerging technologies such as gene therapy and Nanomedicines. As awareness of the condition improves, novel medicines that boost patient outcomes and quality of life are expected to emerge, significantly changing the face of breast cancer treatment.

Will Rising Prevalence of Genetic Predisposition Drive the Breast Cancer Therapeutics Market?

The increasing frequency of hereditary predisposition to breast cancer is becoming a major driver of the breast cancer treatments industry. As knowledge rises and genetic testing becomes more widely available, an increasing number of people are finding their hereditary risk factors, allowing for earlier interventions and specialized treatment options. According to the National Cancer Institute, an estimated 510% of breast cancer occurrences are hereditary, caused by faulty genes passed down from parent to kid. In March 2024, in a significant study published in the Journal of Clinical Oncology, researchers discovered that between 2019 and 2023, the number of women getting genetic testing for BRCA1 and BRCA2 mutations grew by 67%. Increased testing has led to earlier detection and action, raising demand for preventive measures and targeted therapies.

In May 2023, AstraZeneca reported a 28% year-over-year growth in sales of Lynparza, a PARP inhibitor used to treat BRCA-mutated breast cancer. Similarly, Myriad Genetics said in January 2024 that demand for its BRACAnalysis CDx test, which identifies patients with BRCA mutations, had increased by 35% from the previous year. On the regulatory front, the United States Food and Drug Administration (FDA) approved two novel targeted treatments for BRCA-mutated breast cancers in 2023, broadening therapy choices for patients with hereditary risk. Furthermore, in September 2023, the National Institutes of Health announced a USD 50 Million project to enhance access to genetic testing and counseling services, particularly in underprivileged areas. These advancements, together with the American Cancer Society's forecast that around 297,790 new cases of invasive breast cancer will be identified in women in the United States by 2024, emphasizing the growing necessity of treating genetic risk in breast cancer therapies.

Will Increasing Cost of Advanced Chemotherapies Hinder the Growth of the Breast Cancer Therapeutics Market?

The rising expense of sophisticated chemotherapies is expected to stymie the growth of the breast cancer therapeutics market by limiting access to these critical treatments for many patients. As healthcare systems face budget restrictions and growing prescription prices, patients may struggle to afford out-of-pocket expenses, particularly in areas with limited insurance coverage. This cost barrier can cause delays in treatment commencement, less adherence to prescribed medications, and eventually inferior health outcomes, severely influencing total market growth.

Furthermore, rising costs may cause healthcare providers and payers to implement more stringent reimbursement criteria, making it difficult for new, innovative therapies to acquire market acceptability. As a result, pharmaceutical companies may have difficulties in launching and marketing advanced chemotherapies, perhaps resulting to a reduction in R&D investments. This could hinder innovation and prevent the launch of potentially life-saving treatments, thus restricting market expansion and lowering the number of options available to patients and healthcare providers.

Category-Wise Acumens

Will Rising Demand of HER2 Inhibitors Drive the Breast Cancer Therapeutics Market?

The rising demand for HER2 inhibitors is expected to considerably boost the breast cancer treatments market, owing to the increasing prevalence of HER2-positive breast cancer and the effectiveness of these targeted therapies. HER2 inhibitors, including trastuzumab (Herceptin) and newer medicines like neratinib and tucatinib, have shown significant success in improving patient outcomes and overall survival rates. For instance, in May 2023, the United States Food and Drug Administration (FDA) approved trastuzumab deruxtecan (Enhertu) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have had two or more previous anti-HER2-based regimens. This clearance demonstrates the ongoing innovation and growth of treatment choices in this field, which fuels demand and increases competition among pharmaceutical companies.

In June 2023, Daiichi Sankyo announced good results from clinical studies for DS-8201, a new HER2-targeted medication, indicating a potential breakthrough in treatment for HER2-positive breast cancer patients. Government initiatives and financing for breast cancer research are also improving the landscape, as evidenced by the National Cancer Institute's grant program inaugurated in March 2023 to assist the development of new HER2-targeted medicines. This convergence of demand, innovation, and regulatory backing is expected to drive the breast cancer treatments market ahead, particularly in the HER2 inhibitor category.

The mitotic inhibitors market is also expanding rapidly, driven by rising demand for combination therapies and the need for effective treatments in triple-negative breast cancer (TNBC). Paclitaxel and docetaxel are important agents in the treatment of several forms of breast cancer, and their use in combination with other therapies is becoming more common. As research advances and new mitotic inhibitors are created, this industry is likely to experience significant expansion, particularly as healthcare providers strive to diversify therapy choices for patients who may not respond to conventional medicines.

Will Increasing Usage of Chemotherapy Fuel the Breast Cancer Therapeutics Market?

Chemotherapy is likely to propel the breast cancer treatments market as it remains a key treatment for various stages of the disease. Chemotherapy is especially important for individuals with aggressive forms of breast cancer, such as triple-negative breast cancer (TNBC), where treatment options are frequently limited. Recent advancements in chemotherapy regimens, such as the incorporation of novel drugs that reduce adverse effects while increasing efficacy, are adding to its enduring appeal. For instance, in July 2023, the FDA granted rapid clearance for sacituzumab govitecan (Trodelvy) as a therapy for patients with unresectable locally advanced or metastatic TNBC who had received at least two previous regimens. This approval demonstrates the continuous commitment to improve chemotherapy choices and increasing its role in breast cancer treatment.

Furthermore, in April 2023, government programs, such as the National Cancer Institute's funding program, which began, prioritize support for research into novel chemotherapeutic techniques. These findings suggest that the growing reliance on chemotherapy, together with ongoing innovations and supporting government frameworks, will likely fuel expansion in the breast cancer therapies market.

Radiation therapy is also expanding rapidly, especially as part of a multidisciplinary approach to breast cancer treatment. Radiation technology advancements, including as intensity-modulated radiation therapy (IMRT) and partial breast irradiation, have enhanced treatment precision and reduced side effects, resulting in increased patient and doctor acceptability. Furthermore, the tendency toward de-escalation of therapies in early-stage breast cancer, where radiation therapy might serve as a less invasive option after surgery, contributes to its growing significance.

Country/Region-wise

Will Rising Widespread Access to Targeted Therapies and Immunotherapies in North America Drive the Breast Cancer Therapeutics Market?

The increasing availability of targeted treatments and immunotherapies is expected to significantly impact the breast cancer therapeutics market in North America. As healthcare practitioners adopt more novel treatment choices, patients benefit from better outcomes and fewer side effects than traditional medications. According to recent statistics, the use of targeted therapies such as HER2 inhibitors and CDK4/6 inhibitors has increased patient survival rates, with studies demonstrating a 33% reduction in the risk of disease progression in hormone receptor-positive breast cancer patients who receive these therapies. In August 2023, the FDA expanded the indication for palbociclib (Ibrance), a CDK4/6 inhibitor, to cover first-line treatment with aromatase inhibitors, demonstrating the rising acceptance and integration of targeted medicines in clinical practice.

Furthermore, government measures are promoting greater access to these treatments. For instance, the Biden administration's focus on healthcare reforms has resulted in greater Medicare coverage for immunotherapies, making it simpler for patients to get treatments like pembrolizumab (Keytruda), which has been demonstrated to be effective in triple-negative breast cancer. According to in September 2023 study by the American Society of Clinical Oncology (ASCO), around 65% of breast cancer patients now have access to targeted treatments and immunotherapies, up from 50% two years before. This increased trend in access, together with continuous research and development efforts by firms like Genentech and Merck, is likely to further fuel the growth of the breast cancer treatments market in North America, offering patients with more effective treatment alternatives.

Will Rising Awareness of Breast Cancer in Asia Pacific Propel the Breast Cancer Therapeutics Market?

Rising breast cancer awareness in the Asia Pacific region is expected to considerably drive the breast cancer treatments market as more people appreciate the value of early detection and treatment. Educational initiatives and community outreach projects have helped raise awareness of breast cancer risk factors and screening methods. In October 2023, According to a World Health Organization (WHO) report published, the incidence of breast cancer in Asia has climbed by nearly 20% over the last decade, emphasizing the critical need for better therapies. This increased awareness has resulted in higher screening rates and subsequent diagnoses, driving demand for a wide range of treatment choices, including targeted medicines and chemotherapy.

Furthermore, government initiatives are playing an important role in increasing access to breast cancer therapies in the region. For example, in September 2023, the Indian government announced a new national breast cancer control program aimed at improving screening and treatment facilities across the country, hence increasing access to sophisticated therapies. Similarly, Roche and the Chinese government formed a collaboration in August 2023 to provide access to HER2-targeted treatments in underprivileged areas. According to research from the Asia Pacific Oncology Society, as awareness grows, the market for breast cancer therapies is expected to rise at a compound annual growth rate (CAGR) of 9.5% until 2028. This convergence of increased awareness and supported government efforts is projected to considerably enhance breast cancer therapeutics market in the Asia Pacific area, resulting in better patient outcomes and survival rates.

Competitive Landscape

The competitive landscape of the breast cancer therapeutics market is marked by intense innovation, with a strong focus on targeted therapies, immunotherapies, and personalized medicine. Numerous mid-sized pharmaceutical and biotech companies are actively developing novel therapies aimed at improving efficacy and reducing side effects compared to traditional chemotherapy. Companies are leveraging advancements in precision medicine, particularly in hormone receptor-positive (HR+), HER2-positive, and triple-negative breast cancer (TNBC), to offer more effective treatments based on the molecular profile of patients.

Some of the prominent players operating in the breast cancer therapeutics market include:

AstraZeneca plc

Eisai Co. Ltd.

Eli Lilly and Company

Roche Diagnostics

Novartis AG

Pfizer, Inc.

Celgene

Sanofi S.A.

Teva Pharmaceutical

GlaxoSmithKline plc.

Amgen

Merck

Latest Developments

In August 2023, Merck announced that the FDA had increased its approval of pembrolizumab (Keytruda) for the treatment of triple-negative breast cancer in conjunction with chemotherapy for certain patients. This approach emphasizes immunotherapy's growing importance in treating aggressive breast cancer forms.

In September 2023, The Indian government launches a countrywide breast cancer control program to improve screening, diagnosis, and treatment accessibility. This program, which is funded by collaborations with pharmaceutical companies, is projected to enhance outcomes for breast cancer patients nationwide.

In September 2023, Novartis reported encouraging findings from a study using ribociclib (Kisqali) in combination with endocrine therapy for premenopausal women with hormone receptor-positive breast cancer. The results showed improved outcomes, confirming Kisqali as a key player in the breast cancer therapies scene.

1 INTRODUCTION OF GLOBAL BREAST CANCER THERAPEUTICS MARKET

1.1 Introduction of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL BREAST CANCER THERAPEUTICS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY DRUG CLASS

5.1 Overview
5.2 HER2 Inhibitors
5.3 Mitotic Inhibitors

6 GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY THERAPY

6.1 Overview
6.2 Chemotherapy
6.3 Radiation Therapy

7 GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East and Africa

8 GLOBAL BREAST CANCER THERAPEUTICS MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 AstraZeneca plc
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 Eisai Co. Ltd.
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 Eli Lilly and Company
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Roche Diagnostics
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 Novartis AG
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 Pfizer Inc.
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 Celgene
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
9.8 Sanofi S.A.
- 9.8.1 Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Outlook
- 9.8.4 Key Developments
9.9 Teva Pharmaceutical
- 9.9.1 Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Outlook
- 9.9.4 Key Developments
9.10 GlaxoSmithKline plc.
- 9.10.1 Overview
- 9.10.2 Financial Performance
- 9.10.3 Product Outlook
- 9.10.4 Key Developments